ID   CP51C_ASPFN             Reviewed;         513 AA.
AC   B8NUK6;
DT   26-FEB-2020, integrated into UniProtKB/Swiss-Prot.
DT   03-MAR-2009, sequence version 1.
DT   10-FEB-2021, entry version 69.
DE   RecName: Full=Sterol 14-alpha demethylase {ECO:0000303|PubMed:22314539};
DE            EC=1.14.14.154 {ECO:0000250|UniProtKB:Q4WNT5};
DE   AltName: Full=Cytochrome P450 monooxygenase 51C {ECO:0000303|PubMed:22314539};
DE   AltName: Full=Ergosterol biosynthesis protein cyp51C {ECO:0000303|PubMed:22314539};
GN   Name=cyp51c {ECO:0000303|PubMed:22314539}; ORFNames=AFLA_100590;
OS   Aspergillus flavus (strain ATCC 200026 / FGSC A1120 / NRRL 3357 / JCM 12722
OS   / SRRC 167).
OC   Eukaryota; Fungi; Dikarya; Ascomycota; Pezizomycotina; Eurotiomycetes;
OC   Eurotiomycetidae; Eurotiales; Aspergillaceae; Aspergillus;
OC   Aspergillus subgen. Circumdati.
OX   NCBI_TaxID=332952;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 200026 / FGSC A1120 / NRRL 3357 / JCM 12722 / SRRC 167;
RX   PubMed=25883274; DOI=10.1128/genomea.00168-15;
RA   Nierman W.C., Yu J., Fedorova-Abrams N.D., Losada L., Cleveland T.E.,
RA   Bhatnagar D., Bennett J.W., Dean R., Payne G.A.;
RT   "Genome sequence of Aspergillus flavus NRRL 3357, a strain that causes
RT   aflatoxin contamination of food and feed.";
RL   Genome Announc. 3:E0016815-E0016815(2015).
RN   [2]
RP   MUTAGENESIS OF SER-240.
RX   PubMed=22314539; DOI=10.1128/aac.05477-11;
RA   Liu W., Sun Y., Chen W., Liu W., Wan Z., Bu D., Li R.;
RT   "The T788G mutation in the cyp51C gene confers voriconazole resistance in
RT   Aspergillus flavus causing aspergillosis.";
RL   Antimicrob. Agents Chemother. 56:2598-2603(2012).
RN   [3]
RP   MUTAGENESIS OF TYR-319.
RX   PubMed=26248359; DOI=10.1128/aac.00637-15;
RA   Paul R.A., Rudramurthy S.M., Meis J.F., Mouton J.W., Chakrabarti A.;
RT   "A novel Y319H substitution in CYP51C associated with azole resistance in
RT   Aspergillus flavus.";
RL   Antimicrob. Agents Chemother. 59:6615-6619(2015).
RN   [4]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=29311090; DOI=10.1128/aac.01928-17;
RA   Sharma C., Kumar R., Kumar N., Masih A., Gupta D., Chowdhary A.;
RT   "Investigation of multiple resistance mechanisms in voriconazole-resistant
RT   Aspergillus flavus clinical isolates from a chest hospital surveillance in
RT   Delhi, India.";
RL   Antimicrob. Agents Chemother. 62:0-0(2018).
RN   [5]
RP   INDUCTION.
RX   PubMed=31321335; DOI=10.18502/cmm.5.2.1158;
RA   Akbari Dana M., Hashemi S.J., Daei Ghazvini R., Khodavesi S., Modiri M.,
RA   Nazemi L., Darabian S., Rezaie S.;
RT   "Effect of benomyl and diazinon on acquired azole resistance in Aspergillus
RT   flavus and expression of mdr1 and cyp51c genes.";
RL   Curr. Med. Mycol. 5:27-32(2019).
CC   -!- FUNCTION: Cytochrome P450 monooxygenase involved in the biosynthesis of
CC       ergosterol (By similarity). The existence of several duplicated sterol
CC       14-alpha demethylase genes could be a good strategy to modulate the
CC       composition and fluidity of the cell membrane (By similarity).
CC       Catalyzes C14-demethylation of erburicol to produce 4,4,24-trimethyl
CC       cholesta-8,24(28)-dien-3-beta-ol (By similarity). As a target of azole
CC       drugs, plays a crucial role in azole drug susceptibility
CC       (PubMed:26248359). {ECO:0000250|UniProtKB:Q4WNT5,
CC       ECO:0000269|PubMed:26248359, ECO:0000269|PubMed:29311090}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 14alpha-methyl steroid + 3 O2 + 3 reduced [NADPH--
CC         hemoprotein reductase] = a Delta(14) steroid + formate + 4 H(+) + 4
CC         H2O + 3 oxidized [NADPH--hemoprotein reductase];
CC         Xref=Rhea:RHEA:54028, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:15740, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210,
CC         ChEBI:CHEBI:138029, ChEBI:CHEBI:138031; EC=1.14.14.154;
CC         Evidence={ECO:0000250|UniProtKB:Q4WNT5};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:54029;
CC         Evidence={ECO:0000250|UniProtKB:Q4WNT5};
CC   -!- COFACTOR:
CC       Name=heme; Xref=ChEBI:CHEBI:30413;
CC   -!- PATHWAY: Steroid biosynthesis; sterol biosynthesis.
CC       {ECO:0000250|UniProtKB:Q4WNT5}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane {ECO:0000305};
CC       Single-pass membrane protein {ECO:0000255}.
CC   -!- INDUCTION: Over-expressed in azole-resistant clinical isolates
CC       (PubMed:29311090). Expression decreases upon exposure to diazinon and
CC       increases upon exposure to benomyl (PubMed:31321335).
CC       {ECO:0000269|PubMed:29311090, ECO:0000269|PubMed:31321335}.
CC   -!- MISCELLANEOUS: Mutations of Ser-240 or Tyr-319 lead to the resistance
CC       to azoles, clinical drugs used to inhibit the activity and kill
CC       Aspergillus fumigatus cells during infections.
CC       {ECO:0000269|PubMed:22314539, ECO:0000269|PubMed:26248359}.
CC   -!- SIMILARITY: Belongs to the cytochrome P450 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; EQ963484; EED46395.1; -; Genomic_DNA.
DR   RefSeq; XP_002383931.1; XM_002383890.1.
DR   SMR; B8NUK6; -.
DR   STRING; 5059.CADAFLAP00011796; -.
DR   EnsemblFungi; EED46395; EED46395; AFLA_100590.
DR   GeneID; 7912940; -.
DR   KEGG; afv:AFLA_100590; -.
DR   VEuPathDB; FungiDB:AFLA_100590; -.
DR   eggNOG; KOG0684; Eukaryota.
DR   HOGENOM; CLU_001570_15_0_1; -.
DR   OMA; QRCVKET; -.
DR   UniPathway; UPA00766; -.
DR   Proteomes; UP000001875; Unassembled WGS sequence.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0020037; F:heme binding; IEA:InterPro.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0008398; F:sterol 14-demethylase activity; TAS:PHI-base.
DR   GO; GO:0016126; P:sterol biosynthetic process; IEA:UniProtKB-UniPathway.
DR   Gene3D; 1.10.630.10; -; 1.
DR   InterPro; IPR001128; Cyt_P450.
DR   InterPro; IPR017972; Cyt_P450_CS.
DR   InterPro; IPR002403; Cyt_P450_E_grp-IV.
DR   InterPro; IPR036396; Cyt_P450_sf.
DR   Pfam; PF00067; p450; 1.
DR   PRINTS; PR00465; EP450IV.
DR   PRINTS; PR00385; P450.
DR   SUPFAM; SSF48264; SSF48264; 1.
DR   PROSITE; PS00086; CYTOCHROME_P450; 1.
PE   1: Evidence at protein level;
KW   Endoplasmic reticulum; Glycoprotein; Heme; Iron; Membrane; Metal-binding;
KW   Monooxygenase; Oxidoreductase; Reference proteome; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..513
FT                   /note="Sterol 14-alpha demethylase"
FT                   /id="PRO_0000448856"
FT   TRANSMEM        8..28
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   REGION          105..106
FT                   /note="Inhibitor binding"
FT                   /evidence="ECO:0000250|UniProtKB:E9QY26"
FT   METAL           453
FT                   /note="Iron (heme axial ligand)"
FT                   /evidence="ECO:0000250|UniProtKB:Q16850"
FT   BINDING         106
FT                   /note="Inhibitor"
FT                   /evidence="ECO:0000250|UniProtKB:E9QY26"
FT   BINDING         218
FT                   /note="Inhibitor; via carbonyl oxygen"
FT                   /evidence="ECO:0000250|UniProtKB:E9QY26"
FT   BINDING         364
FT                   /note="Inhibitor"
FT                   /evidence="ECO:0000250|UniProtKB:E9QY26"
FT   BINDING         365
FT                   /note="Inhibitor; via carbonyl oxygen"
FT                   /evidence="ECO:0000250|UniProtKB:E9QY26"
FT   CARBOHYD        32
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        332
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   MUTAGEN         240
FT                   /note="S->A: Leads to resistance to azole compounds."
FT                   /evidence="ECO:0000269|PubMed:22314539"
FT   MUTAGEN         319
FT                   /note="Y->H: Leads to resistance to azole compounds."
FT                   /evidence="ECO:0000269|PubMed:26248359"
SQ   SEQUENCE   513 AA;  57500 MW;  84124102924868B5 CRC64;
     MSWPRIGAYA LLAFVAIMAL NVTYQFLFRM LNKTRPPLVF HWIPFIGSTI HYGMDPYGFF
     FSCREKYGDI FTFILLGRPT TVYLGTQGNE FILNGKLKDV NAEEVYSPLT TPVFGSDVVY
     DCPNSKLIEQ KKFIKFGLSQ AALEAHVPLI EKEVEDYLAM SPNFHGTSGE VDIPAAMAEI
     TIFTAGSALQ GEEVRSKLTT EFAVLYHDLD KGFTPINFML PWAPLPHNKK RDAAHARMRS
     IYIDIINKRR NAGDNVPEKL DMIGNLMQCT YKNGQPLPDK EIAHIMITLL MAGQHSSSSI
     SSWIMLRLAS QPAVVEELYQ EQLANLERTG PNGSLAPLQY KDFDNLPLHQ NVIRETLRLH
     SSIHSLLRKV KNPLPVPGTP YVIPTSHVLL AAPGVTALSD EYFPNAMAWD PHRWETQAPQ
     ENNKDDIVDY GYGAMSKGTS SPYLPFGAGR HRCIGEKFAY LNLAVIVATM VRHLRFSNLD
     GQTGVPDTDY SSLFSGPMKP ARIRWERRAA KSG
//
